NEW YORK,
June 12, 2017 /PRNewswire/
-- Genpact (NYSE: G), a global professional services firm
focused on delivering digital transformation for clients, is
investing in leading digital technologies that are transforming
industries. Genpact's PVAI will be the life sciences
industry's first fully-integrated, end-to-end adverse event (AE)
processing solution, leveraging intelligent automation to not only
dramatically reduce the effort of processing adverse events, but
also to enable an AI-driven level of real-time predictive analytics
and actionable insight not previously possible.
As life sciences companies face escalating AE volumes for
their products and increasing pressure to improve quality and
compliance while reducing costs, they are looking for breakthrough
solutions to help them transform their pharmacovigilance
operations. Genpact's PVAI offering brings together and integrates
optical character recognition, robotic process automation, natural
language processing, and machine learning technologies to
automatically extract and code AE data from unstructured and
semi-structured source documents – eliminating manual workflow,
saving pharmaceutical companies significant time and resources, and
helping to establish a scalable PV operating model. Most
importantly, the solution continuously builds predictive insights
as more and more AE goes through it over time.
"Industry leaders have stated that the current
manually-intensive approach to AE processing is simply not
sustainable and needs an innovative approach. Through robust pilot
testing with clients, our new PVAI solution has proven that the
vast majority of case processing can be successfully automated in a
fraction of the time and cost," said Balkrishan 'BK' Kalra,
senior vice president and business leader, Consumer Goods, Retail,
Life Sciences and Healthcare, Genpact. "We continue to
invest in PVAI and are excited to bring this holistic, unique and
market-leading, AI-driven digital proposition to the
industry."
As part of its investments in PVAI, Genpact recently
acquired the assets and team of November Research Group (NRG), a
Berkeley, California-based leading
provider of product vigilance software. The transaction added NRG's
domain expertise and fully-featured pharmacovigilance
Software-as-a-Service, contributing to PVAI's pioneering approach
to automating drug safety operations in the life sciences industry.
Terms of the deal were not disclosed.
"The November Research Group team is very excited to be
part of the Genpact PVAI team and combining our deep domain
expertise and our PV solutions with their AE data extraction
engine, analytics, and innovative AI approach to provide a truly
game-changing PV solution," said Brad
Gallien, vice president, November Research Group.
"Together, we are creating a new paradigm for drug
safety."
Genpact currently serves the majority of global life
sciences companies, helping pharmaceutical and medical devices
companies pursue global growth, achieve cost reduction, increase
speed to market, and improve regulatory compliance by
providing a range of digital solutions, analytics services,
and business process transformation expertise. Genpact has a large
life sciences regulatory services
business stemming from its acquisition of Pharmalink in
2014.
More information about Genpact's PVAI capabilities can be
found at http://www.genpact.com/pvai.
Interested parties may also learn more about Genpact's services for
life sciences companies at
http://www.genpact.com/what-we-do/industries/life-sciences/.
About November Research
Group
November Research Group is a software
development company focused on the development of commercial
applications in product vigilance. The core team of software
developers and quality assurance engineers have been developing
software in this space for over 20 years and have led and
participated in the development of the biggest software solutions
in Pharmacovigilance, including EventNet/Oracle AERS, Relsys/Oracle
Argus, and PRIMO Regulatory. Our current portfolio of
products includes applications to streamline case intake, utilize
mobile AE/PC intake tools, case management, facilitate business
user access to pharmacovigilance data, and analytic solutions built
on "big data" platforms. For more information, visit
www.novemberresearch.com.
About Genpact
Genpact (NYSE: G) is
a global professional services firm focused on delivering digital
transformation for our clients, putting digital and data to work to
create competitive advantage. We do this by integrating lean
principles, design thinking, analytics and digital technologies
with our domain and industry expertise to deliver disruptive
business outcomes – an approach we call Lean DigitalSM.
We deliver value to our clients in two ways – through digital-led,
domain-enabled solutions that drive innovation, and through
intelligent operations enabled by digital that design, transform
and run clients' operations. Our approach is continually refined in
one of the world's largest digital process sandboxes, where we test
and improve thousands of processes. For two decades, first as a
General Electric division and since 2005 as an independent company,
we have been passionately serving our clients. We generate impact
for clients from the Fortune Global 500 and beyond, and
employ over 77,000 people in more than 20 countries, with key
offices in New York City,
Palo Alto, London, and Delhi. For additional
information, visit
www.genpact.com. Follow
Genpact on
LinkedIn,
Twitter,
YouTube, and
Facebook.
For more information:
Gail
Marold
(Genpact Media
Relations)
gail.marold@genpact.com
+1
919-345-3899
|
Matt
Panichas
(for Genpact
U.S.)
mpanichas@peppercomm.com
+1
212-931-6190
|
Mark
Pinnes
(for Genpact
U.K.)
mpinnes@peppercomm.com
+44 20 7680 7121
|
Rudra
Bose
(for Genpact
India)
rudra.bose@bm.com
+91 9811626585
|
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/genpact-launches-an-artificial-intelligence-ai-based-solution-to-usher-in-a-new-era-of-drug-safety-automation-300472192.html
SOURCE Genpact